Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
- PMID: 15746082
- DOI: 10.1182/blood-2004-10-3932
VSports - Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
"V体育安卓版" Abstract
Rapamycin is an immunosuppressive compound that is currently used to prevent acute graft rejection in humans. In addition, rapamycin has been shown to allow operational tolerance in murine models. However, a direct effect of rapamycin on T regulatory (Tr) cells, which play a key role in induction and maintenance of peripheral tolerance, has not been demonstrated so far. Here, we provide new evidence that rapamycin selectively expands the murine naturally occurring CD4(+)CD25(+)FoxP3(+) Tr cells in vitro. These expanded Tr cells suppress proliferation of syngeneic T cells in vitro and prevent allograft rejection in vivo. Interestingly, rapamycin does not block activation-induced cell death and proliferation of CD4(+) T cells in vitro. Based on this new mode of action, rapamycin can be used to expand CD4(+)CD25(+)FoxP3(+) Tr cells for ex vivo cellular therapy in T-cell-mediated diseases VSports手机版. .
Publication types
- Actions (V体育官网入口)
MeSH terms
- Actions (VSports手机版)
- V体育官网 - Actions
- VSports注册入口 - Actions
- V体育官网入口 - Actions
- "VSports手机版" Actions
- VSports手机版 - Actions
- "V体育平台登录" Actions
- Actions (V体育官网)
- VSports最新版本 - Actions
- VSports注册入口 - Actions
- "VSports注册入口" Actions
Substances
- Actions (V体育ios版)
- Actions (V体育安卓版)
- "VSports手机版" Actions
- "V体育2025版" Actions
- "VSports" Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials

